Sponsor Pipeline

Neurodawn Pharmaceutical Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
1
Recruiting
1
Phase 3
1
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-07-23 NCT07721545 Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction Phase 2/3 Not Yet Recruiting
Active Trials by Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT07721545 Y-6 Sublingual Tablets for Acute Penetrating Artery Infarction Perforating Artery Infarction Not Yet Recruiting
Phase 2
NCT07275762 Y-4 to Treat the Postherpetic Neuralgia Postherpetic Neuralgia Recruiting
Phase 1/2
NCT07166380 RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction Transcranial Bone Marrow Injection Not Yet Recruiting
Phase 1
NCT07055412 Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects Pharmacokinetic Differences Not Yet Recruiting
NCT07618715 Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S… Healthy Male and Female Subjects Not Yet Recruiting
Disease Areas
Get alerts when Neurodawn Pharmaceutical Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free